-
Summit Dialogue | Professors Zhang Guojun & Michael Gnant: New Frontiers in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Editor’s note: For patients with HER2-positive breast cancer, neoadjuvant treatment strategies are rapidly evolving—from traditional dual HER2 blockade to the fast-emerging era of antibody–drug conjugates (ADCs). Recently, Chinese-developed anti-HER2 ADCs…
-
SABCS China Voice | Professor Wang Biyun: Beware of ER Loss — Study Reveals Poor Prognosis in Patients Converting from ER-Positive to ER-Negative
Study Overview Title Clinical Outcomes of ER-Positive to Negative Conversion Versus De Novo Triple-Negative Breast Cancer: Evidence from an ^18F-FES PET/CT–Guided Study Background During the course of disease, patients with…
-
SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Reshape Breast Cancer Neoadjuvant Therapy
Editor’s Note As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…
-
SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Redefine Neoadjuvant Breast Cancer Treatment
Study Overview Background With intensified adjuvant CDK4/6i therapy, the absolute improvement in invasive disease-free survival (IDFS) ranges from 4.9% to 7.6%. Given treatment-related adverse events and economic burden, identifying patients…
-
SABCS China Voice | Professors Yan Min & Lü Huimin: U-BOMB-HER Study Advances Treatment of HER2-Positive Brain Metastases
PS5-01-13 — Utidelone Plus Bevacizumab for the Treatment of HER2-Positive Breast Cancer Brain Metastases (U-BOMB-HER): A Multicenter, Single-Arm Phase II Study Study Overview Background Although novel HER2-targeted agents, including tyrosine…
-
SABCS China Voice | Professor Yan Min’s Team: Post-PERMEATE Study Clarifies Radiotherapy Timing in HER2-Positive Brain Metastases
Editor’s Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…
-
ASH Global Perspectives | Prof. Hanny Al-Samkari: Efficacy, Safety, and Dose Optimization of Ianalumab + Eltrombopag in Second-Line ITP
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…
-
ASH Global Perspectives | Professor Jeff Sharman: How Can We Reshape Treatment Strategies for Elderly Patients With DLBCL?
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of lymphoma, but its management is particularly challenging in elderly patients. Standard R-CHOP chemotherapy is often poorly tolerated in…
Connecting Medical Expertise through Media